DCT & HYBRID CLINICAL TRIALS

Huma powers digital-first research accelerating therapies for patients

Our award-winning technology supports decentralized and hybrid clinical trials that get effective treatments to patients faster. Our DCT platform can improve trial participation, diversity, engagement and efficiency, at scale.

Transforming research

1.0M

Active users across
our platforms1

0+

Highly configurable self-service platform with library of modules and capacity to connect to 100s of devices1

Prix Galien
International 2022
Award Winner2

Selected to power some of the world's largest DCTs including five countries and languages across two continents

Huma’s DCT platform capabilities

Powering some of the world’s largest DCTs, Huma enables better research by remotely collecting real-world data.

Recruitment

Our platform supports multiple participant recruitment strategies, including social media and marketing

Eligibility screening and onboarding

Access broader populations and identify suitable participants with remote screening, and onboard them using ID verification

eConsent

Seamlessly obtain informed consent with engaging and educational content that can build trust and support retention³

Carers and proxies

Increase inclusivity by allowing participants to add carers and proxies who can respond to study activities on their behalf

Slider image number 0
Slider image number 1
Slider image number 2
Slider image number 3
Slider image number 4
Slider image number 5
Slider image number 6
Slider image number 7

eCOA/ePRO

Use questionnaires, videos and images to facilitate robust collection of research-grade clinical data via app or web

Connected devices

Enabling capture of vital and non-vital signs through connected medical devices, sensors and wearables - with over 1m devices included to date

Telemedicine

Provide tele-visit and tele-consent, messaging and clinical support through secure video and audio consultations, to make logistics and communication easier³

Educational content

Engage and inform participants with educational content about the research study, how it will operate, ongoing support and relevant contact details

  • Recruitment
  • eCOA/ePRO
  • Eligibility screening and onboarding
  • Connected devices
  • eConsent
  • Telemedicine
  • Carers and proxies
  • Educational content

Our platform supports multiple participant recruitment strategies, including social media and marketing

Use questionnaires, videos and images to facilitate robust collection of research-grade clinical data via app or web

Access broader populations and identify suitable participants with remote screening, and onboard them using ID verification

Enabling capture of vital and non-vital signs through connected medical devices, sensors and wearables - with over 1m devices included to date

Seamlessly obtain informed consent with engaging and educational content that can build trust and support retention³

Provide tele-visit and tele-consent, messaging and clinical support through secure video and audio consultations, to make logistics and communication easier³

Increase inclusivity by allowing participants to add carers and proxies who can respond to study activities on their behalf

Engage and inform participants with educational content about the research study, how it will operate, ongoing support and relevant contact details

  • Site performance analytics

    Manage multiple sites within a web-based portal, with data on target enrolment numbers, recruitment performance and study protocol compliance

  • Participant-level monitoring

    Allows real-time visualisation of participant data, with built-in flagging systems to detect non-compliance or clinical events, to intervene as necessary

  • Permission layers

    Smart analytics dashboards with deep and configurable permission layers for easy access to data for all relevant stakeholders

  • Telemedicine

    Sponsors and CROs can securely communicate with participants through messages, video and audio calls. Remote visits can be scheduled or participants can be contacted immediately³

  • EDC interoperability and data exporting

    Participant-generated data can be exported at any time from Huma's systems, in multiple file formats. The data can then be consumed onwards and refresh EDC systems and registries

  • Call-centre support

    Participants who do not have access to a smartphone can ring a call-centre, whose staff can use the web portal to answer questionnaires on their behalf

  • Site performance analytics

    Manage multiple sites within a web-based portal, with data on target enrolment numbers, recruitment performance and study protocol compliance

  • Participant-level monitoring

    Allows real-time visualisation of participant data, with built-in flagging systems to detect non-compliance or clinical events, to intervene as necessary

  • Permission layers

    Smart analytics dashboards with deep and configurable permission layers for easy access to data for all relevant stakeholders

  • Telemedicine

    Sponsors and CROs can securely communicate with participants through messages, video and audio calls. Remote visits can be scheduled or participants can be contacted immediately³

  • EDC interoperability and data exporting

    Participant-generated data can be exported at any time from Huma's systems, in multiple file formats. The data can then be consumed onwards and refresh EDC systems and registries

  • Call-centre support

    Participants who do not have access to a smartphone can ring a call-centre, whose staff can use the web portal to answer questionnaires on their behalf

Slider image number 0
Slider image number 1
Slider image number 2
Slider image number 3
Slider image number 4
Slider image number 5
Slider image number 0
Slider image number 1
Slider image number 2
Slider image number 3
Slider image number 4
Slider image number 5

Benefits of the platform

How our DCT platform can help accelerate timelines and reduce costs

Faster decision-making with real-
time analytics

Customise dashboards to provide real-time insights regarding site and participant performance, help proactively and safely monitor participants and improve protocol adherence

Keep participants engaged and
improve retention

Intuitive UI design, educational content and notifications to optimise participation and engagement, whilst seamless device connection and tele-visits reduce patient burden

Research-grade data collection

Collect robust, high-quality health data from sensors, devices and questionnaires with our comprehensive platform

Connect and combine

Flexible connection with Electronic Data Capture and other datasets / registries, as well as near real- time access to Electronic Health Records, pharmacy and claims records to build a richer patient profile4

Why Huma?

3,000+ hospitals, clinics and 1.8 million active users supported across Huma platforms1

Huma wins 'pharma's Nobel prize’ 2022 Prix Galien USA for it’s digital health platform3

Modular, flexible design and technology platform to enable rapid configuration of study protocols

Highly-prized user- experience delivering high protocol compliance and retention rates5

Industry-leading and flexible IoMT integration with privileged access to raw wearable data from connected devices

Built to the highest data, privacy and security standards including ISO 27001, Cyber essentials Plus, 21 CFR and TxP compliant

Cloud-agnostic platform that can be deployed globally in any language across multiple therapeutic areas

Request fact sheet

Who we work with

Huma has deployments with top 10 pharmaceutical companies, national governments, major healthcare providers and leading research institutions around the world and was selected to power one of the largest global decentralised clinical trials for AstraZeneca

Partners logos. Partners logos.

Our experience in delivering
better research

  • phase iv trial
  • atrial fibrillation
  • covid-19
  • diabetes

Supporting AstraZeneca with an
international Phase IV study

AstraZeneca selected our DCT platform to support one of the world’s largest decentralized clinical trials. Designed to use remote recruitment, ID verification, and safety data collection through our secure platform, the first patient was recruited less than three months after the project was signed. In order to ensure access for all populations, participants have multiple means to engage and are able to submit data on either an app, web portal or through a call centre.

Watch video

Powering a DCT in atrial fibrillation
with Bayer and Stanford Medicine

Huma, Bayer, Stanford Medicine and the Stanford Center for Digital Health together demonstrated the feasibility, for the first time, of a scalable, fully decentralized cardiovascular intervention trial requiring remote physiologic measurements among participants with atrial fibrillation. The trial had a robust recruitment strategy and strong engagement. Participants successfully transmitted physiologic BP and ECG measurements, tracked OAC adherence, completed regular surveys and televisits using Huma’s DCT platform. The findings provide a strong foundation to inform the design and conduct of future decentralized protocols for cardiovascular trials.

Watch video

Pioneering a decentralized clinical study
with the University of Cambridge

Huma partnered with the University of Cambridge (Medical Research Council Epidemiology Unit) to understand the progression of COVID-19 infection and build predictive models for pre-symptomatic infection. The study uses Huma’s digital platform to remotely collect data from nearly 2,500 participants from the Fenland cohort. This builds on 15 years worth of retrospective data to generate new insights and a joint analytics dataset for digital biomarker discovery.

Watch video

Interventional Trial For High-Risk
Type 2 Diabetes Patients

The study is a collaboration between Huma, Astra Zeneca and Imperial Health Partners. With the initial promising results from the interventional trial that included 600 participants, the aim is to scale the programme nationally, to create a real-world dataset to support high-quality research and transform care pathways for patients with type 2 diabetes, reducing complications and improving outcomes.

Watch video

Regulatory, safety and compliance

Regulatory logo.

ISO certifications

  • ISO 13485: 2016 certified (Medical Devices: Quality Management Systems)
  • ISO 27001: 2013 certified

Medical device registrations

  • CE marked class I Medical Device
  • Registered with the MHRA as a Medical Device
  • US FDA Class I exempt and enforcement discretion

Data protection /
infosec

  • Committed to GDPR compliance
  • NHS Registration on Data Security and Protection Toolkit
  • CyberEssentials / CyberEssentials Plus

US FDA 21 CFR compliances

  • Part 11
  • Part 50
  • Part 820 ff

Talk to us

This field is required

This field is required

This field is required

This field is required

This field is required

Country/Region*
United Kingdom
United States
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of the
Cook Islands
Costa Rica
Cote D"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and Mcdonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic Of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People"S Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People"S Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, The Former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
RWANDA
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe

This field is required

I'm interested in
Companion app for Pharmaceutical companies
Companion app for MedTech companies
Decentralised Clinical Trials (DCT)
Hospital @ Home
Software as a Medical Device (SaMD)
Partnering with Huma
Other

This field is required

Huma is committed to respecting your privacy, and we’ll only use your personal details to provide information you have selected you’re interested in. Review our Privacy Policy for further information.

We’d love to send you our monthly newsletter about our latest work, research and events by email. We’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes.

You’re in control. You can, of course, withdraw your consent at any time. Review our Privacy Policy for further information.

Success message with thumbs up for filling out the form.
One of our team members will be in touch with you shortly.
There was an error submitting your form. Please refresh and try again.

Sources

1. Based on internal data, correct as of June 2022

2. Winner of the 2022 Prix Galien International and 2021 Prix Galien USA awards for digital health (https://huma.com/announcement/huma-prix-galien-2022)

3. Available as per local regulations

4. This is available in the US only and with patient’s consent as part of the study

5. Selected as one of ‘The Most Important Healthcare Design of 2021’ by Fast Company (https://www.fastcompany.com/90667024/health-innovation-by-design-2021)

6. Data from 2021 single-arm, six-month study. Paper accepted

7. Publication in production

8. Data from 2021 pilot study. Full evaluation of the service is in preparation

Cookie settings